Related Experiment Videos
Vancomycin therapy of bacterial endocarditis
Abstract:
Fifteen patients with bacterial endocarditis were treated with vancomycin between 1967 and 1976. The indications for vancomycin therapy were penicillin-cephalosporin allergy in six patients, antibiotic resistant bacteria in six, initial therapy in one and culture-negative endocarditis in two. The causative microorganisms were Staph. epidermidis (four patients), Staph. aureus (two patients), diphtheroids (four patients), viridans streptococci (two patients) and enterococci (one patient). Minimum inhibitory concentrations of vancomycin for these organisms ranged from 0.8 to 3.1 micrograms/ml. The patients received vancomycin for two to 10 weeks (mean five weeks). Cure was achieved in 13 patients, including six with prosthetic valve endocarditis (PVE). Two patients had a relapse of PVE and cultures of blood or heart valve were positive within two months of vancomycin therapy. Vancomycin serum levels did not exceed 50 micrograms/ml, and no serious drug toxicity was encountered in any patient. Three patients had minimal audiogram changes beyond the social hearing range. One patient had mild phlebitis and a rash, and one patient had a transient leukopenia. Vancomycin is an effective nontoxic antibiotic in patients with endocarditis when penicillin or cephalosporin therapy is not appropriate.
Insights
Vancomycin effectively treated bacterial endocarditis in 13 of 15 patients, including those with prosthetic valves or allergies to other antibiotics. This study highlights vancomycin as a safe and effective option when standard therapies are unsuitable.
Area of Science:
- Infectious Diseases
- Pharmacology
- Cardiology
Background:
- Bacterial endocarditis is a serious infection requiring effective antibiotic treatment.
- Penicillin and cephalosporin allergies or antibiotic resistance can complicate treatment choices.
Purpose of the Study:
- To evaluate the efficacy and safety of vancomycin for treating bacterial endocarditis.
- To assess vancomycin's utility in patients with contraindications to penicillin or cephalosporins.
Main Methods:
- Retrospective analysis of 15 patients with bacterial endocarditis treated with vancomycin (1967-1976).
- Recorded indications for vancomycin, causative microorganisms, treatment duration, and patient outcomes.
- Monitored vancomycin serum levels and adverse events.
Main Results:
- Cure achieved in 13 of 15 patients (87%), including six with prosthetic valve endocarditis (PVE).
- Common indications included penicillin-cephalosporin allergy and antibiotic-resistant bacteria.
- Minimal vancomycin-related toxicity observed; transient leukopenia and mild audiogram changes in a few patients.
Conclusions:
- Vancomycin is an effective and generally well-tolerated antibiotic for bacterial endocarditis.
- It serves as a crucial alternative when penicillin or cephalosporin therapy is inappropriate or contraindicated.